|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Background The most common cause of activated protein C (aPC) resistance is a missense substitution (Arg506Gln), known as Factor V Leiden (FVL).
|
30903752 |
2019 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No differences were found for FV G1691A or homozygous MTHFR mutations between neonates with CSVT and their mothers, compared to controls.
|
31025572 |
2019 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The R506Q Factor V-Leiden mutation is now usually characterized using molecular biology, and this technique tends to become the first intention assay for characterization of patients.
|
29162399 |
2017 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this case-control study, we aimed to determine the frequency of prothrombin G20210A and factor V Leiden (FVL) G1691A polymorphisms and protein C, protein S, and antithrombin III deficiencies in the East Algerian population and to investigate whether these genetic factors are associated with VTE.
|
26304686 |
2017 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two variants in the factor 5 gene (F5), rs6025 encoding for the factor V Leiden mutation R506Q, and rs4524 encoding K858R, have been found to be associated with venous thromboembolism.
|
27479824 |
2016 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To assess Factor V Leiden (FVL) (rs6025), Prothrombin G20210A (rs1799963), MTHFR C677T (rs1801133), and MTHFR A1298C (rs1801131) gene mutations as risk factors in the development of retinopathy of prematurity (ROP).
|
27018927 |
2016 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The discovery of the factor V Leiden (FVL) missense mutation (Arg506Gln) causing factor V resistance to the anticoagulant action of activated protein C was a landmark that allowed a better understanding of the basis of inherited thrombotic risk.
|
27797270 |
2016 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study was carried out in 100 patients with hemophilia A. Genotyping for factor V Leiden (FVL) G1691A, prothrombin G20210A, MTHFR C677T, and A1298C mutations was conducted using a real time-polymerase chain reaction (RT-PCR) assay.
|
26891731 |
2016 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Significant differences were found in the frequencies of the genotypes for both the FVL (G1691A) (P<10(-3), odds ratio [OR]=17.4, confidence interval [CI]=6.20-59) and prothrombin (G20210A) (P=.007, OR=5.11, CI=1.30-29) polymorphisms between RVO patients and healthy controls.
|
24630828 |
2014 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V Leiden (FVL) G1691A, Prothrombin (PT) G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T and A128C mutations were evaluated in children with moderate-severe hemophilia A (n = 51) and controls (n = 25).
|
22411997 |
2014 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Risk estimates were unaffected by adjustments for blood type and F5 rs6025 (Factor V Leiden) mutation.
|
23150947 |
2013 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We determined whether the presence of the factor prothrombin gene G20210A variant, factor V gene G1691A mutation (factor V Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms may be risk factors for vascular complications in individuals with SCD.
|
23992124 |
2013 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It has been hypothesized that thrombophilic G1691A factor V Leiden (FVL), if detected well ahead in time among recurrent miscarriages may be a treatable.
|
22990475 |
2013 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
SNP in the following genes demonstrated association with thrombosis risk overall in the discovery or replication cohorts and were assessed using metaanalytic methods: factor V Leiden (FVL) rs6025 (OR 1.85, p = 0.02) and methylenetetrahydrofolate reductase (MTHFR) rs1801133 (OR 0.75, p = 0.04) in whites, and fibrinogen gamma (FGG) rs2066865 (OR 1.91, p = 0.01) in Hispanic Americans.
|
22707612 |
2012 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genetic polymorphisms C677T and A1298C relating to the enzyme methylenetetrahydrofolate reductase (MTHFR), a clotting Factor V Leiden mutation (1691G→A substitution of Factor V Leiden), and the mutant prothrombin 20210A allele were analyzed in this study.
|
22924497 |
2012 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
|
21564075 |
2011 |
|
rs6025
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Factor V Leiden mutation (FVL; c.1601G>A, p.Arg534Gln), the most common aberration underlying activated Protein C resistance, results in disruption of a major anticoagulation pathway and is a leading cause of inherited thrombophilia.
|
21254846 |
2011 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of FVL (G1691A) and FII (G20210A) mutations was carried out using PCR with sequence specific primers.
|
21269570 |
2011 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequency of FVL G1691A and ACE D allele in T2DM patients with microalbuminuria were 1.6 and 57%, respectively and in normoalbuminuric T2DM patients were 4.9 and 58.3%, respectively (P > 0.05).
|
20853144 |
2011 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To find association of angiotensin-converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen (AGT) T704C, methylenetetrahydrofolate reductase (MTHFR) C677T and factor V Leiden (FVL) G1691A polymorphisms with pre-eclampsia (PE) in North Indian women.
|
21564405 |
2011 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eighty DVT patients with the mean age of 42.07 +/- 13.0 years including 44 women and 36 men and 100 sex-matched healthy individuals with the mean age of 37.63 +/- 13.3 years from Kermanshah Province of Iran with ethnic background of Kurd were studied for FVL c.1691G>A, prothrombin g.20210G>A and MTHFR c.677C>T by PCR-restriction fragment length polymorphism (RFLP) method using MnlI, HindIII and HinfI restriction enzymes, respectively.
|
20479641 |
2010 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The G1691A mutation of the factor V gene (factor V Leiden) and the G20210A mutation of the prothrombin gene as risk factors in thrombotic microangiopathies.
|
19448164 |
2009 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most common genetic defect associated with deep vein thrombosis (DVT) is a mutation in the Factor V gene (G1691A), known as Factor V Leiden (FVL).
|
19604111 |
2009 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a 12-member, 3-generation kindred with conjoint inheritance of G1691A factor V Leiden (FVL) and G20210A prothrombin gene (PTG) mutations, identified through a proband with amaurosis fugax and his father with nonarteritic ischemic optic neuropathy (NAION), the authors' hypothesis was that ocular thrombosis was a diagnostic window to familial thrombophilia-thrombosis.
|
18796459 |
2009 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The protein C (PC), protein S, antithrombin activities, homocysteine levels, and factor V Leiden (FVL) G1691A and prothrombin G20210A mutations were evaluated in 191 patients with VTE and 191 controls.
|
17895505 |
2008 |